Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q42356655)
Watch
English
PARP inhibitors: the race is on.
scientific article published on March 2016
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMCID
4984871
retrieved
28 October 2017
editorial
0 references
title
PARP inhibitors: the race is on.
(English)
1 reference
stated in
Europe PubMed Central
PMCID
4984871
retrieved
28 October 2017
author name string
Jessica S Brown
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMCID
4984871
retrieved
28 October 2017
Stan B Kaye
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMCID
4984871
retrieved
28 October 2017
Timothy A Yap
series ordinal
3
1 reference
stated in
Europe PubMed Central
PMCID
4984871
retrieved
28 October 2017
language of work or name
English
0 references
publication date
1 March 2016
1 reference
stated in
Europe PubMed Central
PMCID
4984871
retrieved
28 October 2017
published in
British Journal of Cancer
1 reference
stated in
Europe PubMed Central
PMCID
4984871
retrieved
28 October 2017
volume
114
1 reference
stated in
Europe PubMed Central
PMCID
4984871
retrieved
28 October 2017
issue
7
1 reference
stated in
Europe PubMed Central
PMCID
4984871
retrieved
28 October 2017
page(s)
713-715
1 reference
stated in
Europe PubMed Central
PMCID
4984871
retrieved
28 October 2017
copyright license
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International
start time
1 March 2016
1 reference
stated in
April 2022 Public Data File from Crossref
copyright status
copyrighted
0 references
exact match
https://scigraph.springernature.com/pub.10.1038/bjc.2016.67
0 references
cites work
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984871
retrieved
29 May 2018
BRCAness revisited
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984871
retrieved
29 May 2018
Targeting the DNA Damage Response in Cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984871
retrieved
29 May 2018
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984871
retrieved
29 May 2018
Trapping Poly(ADP-Ribose) Polymerase
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984871
retrieved
29 May 2018
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984871
retrieved
29 May 2018
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984871
retrieved
29 May 2018
The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984871
retrieved
29 May 2018
Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984871
retrieved
29 May 2018
Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984871
retrieved
29 May 2018
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984871
retrieved
29 May 2018
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984871
retrieved
29 May 2018
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984871
retrieved
29 May 2018
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984871
retrieved
29 May 2018
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984871
retrieved
17 August 2018
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4984871
retrieved
17 August 2018
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/27022824
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1038/BJC.2016.67
1 reference
stated in
Europe PubMed Central
PMCID
4984871
retrieved
28 October 2017
PMCID
4984871
1 reference
stated in
Europe PubMed Central
PMCID
4984871
retrieved
28 October 2017
PubMed ID
27022824
1 reference
stated in
Europe PubMed Central
PMCID
4984871
retrieved
28 October 2017
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
